Additional file 1: of Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
Creators: name: Kiessling, Michael
name: Schuierer, Sven
name: Stertz, Silke
name: Beibel, Martin
name: Bergling, Sebastian
name: Knehr, Judith
name: Carbone, Walter
name: ValliĂ¨Re, Cheryl De
name: Tchinda, Joelle
name: Tewis Bouwmeester
name: Seuwen, Klaus
name: Rogler, Gerhard
name: Roma, Guglielmo
Publisher: name: Figshare
Year: 2016
Subjects: subject: Biophysics
subject: Biochemistry
subject: Space Science
subject: Microbiology
subject: FOS: Biological sciences
subject: FOS: Biological sciences
subject: Cell Biology
subject: Genetics
subject: Molecular Biology
subject: Physiology
subject: Biotechnology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: FOS: Chemical sciences
subject: 69999 Biological Sciences not elsewhere classified
subject: Cancer
subject: Inorganic Chemistry
subject: Hematology
subject: 110309 Infectious Diseases
subject: FOS: Health sciences
subject: FOS: Health sciences
subject: 60506 Virology

description: Supplementary Figures. Figure S1. Coverage of the sgRNA library in HCC-827 and CHP-212 cells. a) Coverage of the sgRNA library by deep sequencing at indicated time points for the HCC-827 cell line. Each time point was measured in duplicates and average percentages are represented here. b) Same as in a) but CHP-212 cell line is used instead. Figure S2. Principal Components Analysis (PCA) plots for different time points in HCC-827 and CHP-212 cells. PCA plots representing the sgRNA counts obtained for both cell lines. Figure S3. Histogram plots of the difference between the maximum and the minimum sgRNA fold changes per gene. These histogram plots show the variability among sgRNAs targeting the same gene calculated as the delta between the maximum and the minimum sgRNA fold changes for each gene for the HCC-827 and the CHP-212 cell lines on day 14. Figure S4. Depleted sgRNAs for kinases in HCC-827 and CHP-212 cells. Time points were measured in duplicates and median fold changes are represented here. Dark green colored dots represent the 1 000 non-targeting control sgRNAs and grey colored dots represent the 57 096 targeting sgRNAs. a-d) Scatter plots of fold changes compared to the control time point are shown for the HCC-827 and the CHP-212 cell line. f,g) Scatter plots of fold changes of 57 096 targeting sgRNAs of the HCC-827 and CHP-212 cell lines at indicated time points. e, f) Scatter plot of fold changes for independent replicates at time point day 14 for HCC-827 (S4e) and CHP-212 (S4f), respectively. g,h) Scatter plots of fold changes of 57 096 targeting sgRNAs of the HCC-827 and CHP-212 cell lines at indicated time points. Figure S5. Estimation of off-target effects. a) Scatter plots of mRNA expression levels expressed in FPKMs were compared to depletion by Q1 for the HCC-827 cell line. Of the 5 % most depleted genes which is equal to 1 450 sgRNAs, more than 90 % were expressed with a FPKMâ  &gt;â  1. b) Of the 1 462 most depleted sgRNAs (5 %) for the CHP-212 cell line, more than 87,5 % were expressed with a FPKM &gt;1. Figure S6. MEK inhibitor MEK162 and EGFR inhibitor Erlotinib affected cell viability of the respective cell lines. a,b) HCC-827 and CHP-212 cells were treated with indicated concentrations of Erlotinib (a) or MEK162 (b) and analyzed as described in M&amp;M part. Figure S7. Cytogenetics of HCC-827 and CHP-212 cell lines. (PDF 1451 kb)